Oncimmune Holdings Past Earnings Performance

Past criteria checks 0/6

Oncimmune Holdings has been growing earnings at an average annual rate of 11%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 20.4% per year.

Key information

11.0%

Earnings growth rate

22.0%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate20.4%
Return on equityn/a
Net Margin-258.6%
Last Earnings Update29 Feb 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Oncimmune Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BST:OCY Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
29 Feb 241-321
30 Nov 231-531
31 Aug 231-641
31 Aug 222-551
31 May 223-1092
28 Feb 224-882
30 Nov 213-782
31 Aug 214-682
31 May 214-572
28 Feb 213-571
30 Nov 202-671
31 Aug 201-771
31 May 201-882
29 Feb 200-982
30 Nov 190-992
31 Aug 190-972
31 May 190-862
28 Feb 190-861
30 Nov 180-761
31 Aug 180-751
31 May 180-651
28 Feb 180-641
30 Nov 170-541
31 Aug 170-541
31 May 170-541
28 Feb 170-841
30 Nov 160-1041
31 Aug 160-941
31 May 160-841
31 May 151-221
31 May 141-130

Quality Earnings: OCY is currently unprofitable.

Growing Profit Margin: OCY is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: OCY is unprofitable, but has reduced losses over the past 5 years at a rate of 11% per year.

Accelerating Growth: Unable to compare OCY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OCY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Return on Equity

High ROE: OCY's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies